Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rezolute Announces CFO | Contract Pharma
Breaking News, Promotions & Moves

Rezolute Announces CFO

Keith Vendola, M.D., M.B.A. brings over two decades of experience to the company

Rezolute, Inc. announced that Keith Vendola, M.D., M.B.A., has joined as chief financial officer. 

 
With two decades of expertise in healthcare corporate finance, Dr. Vendola will report directly to Nevan Elam, chief executive officer of Rezolute.
 
“Keith’s finance and extensive deal expertise coupled with his medical background are a perfect fit for Rezolute given our stage of development and strategic goals,” Mr. Elam said. “Keith will play an integral role in moving Rezolute forward as a clinical stage company. I look forward to working closely with him.”

“I am thrilled to join Rezolute,” stated Dr. Vendola. “The team is driven by a passion to develop promising therapeutics that improve the care and lives of patients impacted by metabolic and rare conditions. I am honored to help with this mission.”  

Dr. Vendola previously served as vice president of Competitive Strategy and Chief of Staff at Coherus BioSciences while the market cap exceeded $1 billion. In this role, he interacted extensively with Wall Street and executed multiple financings. In addition, he has served in senior finance and corporate development roles at a variety of pharmaceutical companies and as an investment banker within the healthcare groups of Bank of America Securities and Chase. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters